Bayer to Inject More Than $2 Billion Into Upgrading Manufacturing

Bayer said it plans to spend more than $2 billion over the next three years on strengthening and expanding its drug and biologic manufacturing operations.

Roughly half of the funding will be on cell and gene therapy production, including at its Berkeley, Calif., manufacturing facility.

The company will also spend more than $1 billion on its German manufacturing centers in Berlin, Leverkusen, Bergkamen and Wuppertal, with a focus on parenteral drugs, nonhormonal solids, contrast media, hormone products, therapeutics and new production technologies.